论文部分内容阅读
我科自1998年8月至2000年6月，应用皮下植入用缓释氟脲嘧啶（植入组），同静脉用氟脲嘧啶（对照组）同时联合顺铂治疗食管、贲门癌。结果表明植入组有效率为23．9％，对照组有效率为15．9％（P＞0．05）。植入组和对照组Ⅱ级以上血液学不良反应分别为20．3％和32．2％（P＜0．0
In our department from August 1998 to June 2000, sustained-release fluorouracil (subcutaneously implanted) was used for subcutaneous implantation, and fluorouracil (control) and intravenous cisplatin were simultaneously used for the treatment of esophageal and cardiac cancers. The results showed that the effective rate was 23.9% in the implanted group and 15.9% in the control group (P>0.05). The hematological adverse reactions above grade II in the implanted and control groups were 20.3% and 32.2%, respectively (P<0.0).